Ekso Bionics Q3 rev $4.1M (-11% YoY), loss narrows; announces CMS reimbursement

EKSO BIONICS HOLDINGS, INC.

2024-Q3 EPS reported -$0.42 revenue$12,835,000

Revenue $4.1M (Q3 2024) vs $4.6M (Q3 2023); 33 EksoHealth devices sold.
Gross margin improved to 53.5% from 53.3% on supply chain cost savings.
Net loss narrowed to $2.1M ($0.10/share) from $3.4M ($0.24/share) YoY.
Received CMS reimbursement for Ekso Indego Personal, enabling Medicare coverage for SCI patients.
Cash $8.3M at Sep 30, 2024; raised $5.0M net in underwritten offering during September.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.